GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stock Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,325,096 shares of the company's stock after purchasing an additional 416,386 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.73% of GE HealthCare Technologies worth $259,956,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in shares of GE HealthCare Technologies by 29.8% in the third quarter. JPMorgan Chase & Co. now owns 2,233,603 shares of the company's stock worth $209,624,000 after buying an additional 512,778 shares during the period. Park Avenue Securities LLC raised its holdings in shares of GE HealthCare Technologies by 9.7% during the 4th quarter. Park Avenue Securities LLC now owns 4,450 shares of the company's stock valued at $348,000 after buying an additional 392 shares during the period. Merit Financial Group LLC lifted its position in GE HealthCare Technologies by 3.4% during the 4th quarter. Merit Financial Group LLC now owns 8,820 shares of the company's stock worth $690,000 after acquiring an additional 292 shares in the last quarter. HB Wealth Management LLC boosted its holdings in GE HealthCare Technologies by 24.5% in the 4th quarter. HB Wealth Management LLC now owns 8,366 shares of the company's stock worth $654,000 after acquiring an additional 1,645 shares during the period. Finally, Janney Montgomery Scott LLC boosted its holdings in GE HealthCare Technologies by 17.2% in the 4th quarter. Janney Montgomery Scott LLC now owns 54,529 shares of the company's stock worth $4,263,000 after acquiring an additional 7,994 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GEHC has been the topic of a number of analyst reports. Wells Fargo & Company dropped their price objective on shares of GE HealthCare Technologies from $103.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. The Goldman Sachs Group dropped their price target on shares of GE HealthCare Technologies from $94.00 to $82.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. BTIG Research set a $95.00 target price on GE HealthCare Technologies and gave the company a "buy" rating in a research note on Monday, April 14th. Piper Sandler dropped their target price on GE HealthCare Technologies from $104.00 to $88.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Morgan Stanley cut their price target on GE HealthCare Technologies from $86.00 to $78.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies has an average rating of "Moderate Buy" and an average target price of $88.27.

GE HealthCare Technologies Stock Up 2.8%

Shares of GEHC traded up $1.95 during midday trading on Tuesday, hitting $71.11. The company had a trading volume of 795,308 shares, compared to its average volume of 3,435,530. The stock has a market cap of $32.56 billion, a price-to-earnings ratio of 16.43, a PEG ratio of 3.19 and a beta of 1.21. The company's 50 day moving average price is $69.83 and its 200 day moving average price is $79.41. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52 week low of $57.65 and a 52 week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.10. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $4.78 billion during the quarter, compared to analyst estimates of $4.66 billion. During the same period in the previous year, the company earned $0.90 earnings per share. GE HealthCare Technologies's quarterly revenue was up 2.7% on a year-over-year basis. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies declared that its Board of Directors has initiated a stock buyback program on Wednesday, April 30th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

GE HealthCare Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 15th. Stockholders of record on Friday, April 25th were issued a $0.035 dividend. The ex-dividend date of this dividend was Friday, April 25th. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.20%. GE HealthCare Technologies's dividend payout ratio (DPR) is 2.95%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.